Core Viewpoint - The article emphasizes the importance of value investing and highlights InMode (INMD) as a strong candidate for investors due to its attractive valuation metrics and strong earnings outlook [2][4][6]. Company Analysis - InMode (INMD) currently holds a Zacks Rank of 1 (Strong Buy) and a Value grade of A, indicating it is a top pick for value investors [4]. - The stock has a P/E ratio of 7.73, significantly lower than the industry average P/E of 21.64, suggesting it may be undervalued [4]. - Over the past 12 months, INMD's Forward P/E has fluctuated between 6.86 and 13.19, with a median of 8.37, further indicating its potential for value [4]. Valuation Metrics - InMode's P/B ratio stands at 1.75, which is attractive compared to the industry's average P/B of 5.22, reinforcing the notion of undervaluation [5]. - The P/B ratio for INMD has ranged from 1.73 to 4.91 over the past year, with a median of 2.37, highlighting its current favorable valuation [5]. Earnings Outlook - The combination of InMode's strong earnings outlook and its favorable valuation metrics positions it as an impressive value stock in the current market [6].

YOKNEAM, Israel, Sept. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has approved a share repurchase program of up to 7.68 million ordinary shares. "Following the completion of our share buyback program announced earlier this year, the board's authorization to enact this new share repurchase program demonstrates our ongoing confidence in the long-term outlook of the company," commented Moshe Mizr ...

Company Overview - InMode is an Israeli company that sells medical devices and consumables, focusing on radiofrequency and intense pulsed light technologies for aesthetic procedures [2] - The company's products are high-quality and expensive, often financed by customers, making interest rates a significant factor in revenue generation [2] Stock Performance - InMode's stock has seen a significant decline from a peak of $99 in 2021 to under $16 per share [1] - The company had a large cash position of $729.2 million as of June 30, 2024, with no debt, but failed to execute share buybacks as expected, leading to investor disappointment [3][4] Recent Developments - In October 2023, InMode lowered its full-year guidance, resulting in a 20% drop in stock price, attributed to high interest rates negatively impacting demand [4] - The company has recently initiated share buybacks, repurchasing 8.37 million shares, which is 10% of its outstanding shares, at an average price of $17.97 [11] Financial Outlook - Analysts expect InMode to report an EPS of $1.88 for Fiscal 2024, resulting in a forward P/E of 8.35x, indicating a potential undervaluation [8] - Future EPS growth is projected at 14.1% in 2025 and 8.9% in 2026, with a forward P/E of 6.7x for 2026 [8] Market Conditions - High interest rates have adversely affected InMode's sales, as many customers are delaying purchases until rates decrease [6] - The market anticipates a 68% chance of a 25 basis points interest rate cut by September 2025, which could positively impact InMode's sales [6][7] Valuation Analysis - Current market expectations imply a decline in free cash flow per share of 4.412% annually for the next decade, which is viewed as overly pessimistic for a leading player in the aesthetics medical device market [10][12] - The stock's valuation suggests a forward earnings yield of nearly 15% for 2026, indicating potential for significant upside [12]

YOKNEAM, Israel, Sept. 4, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will present inperson at the 2024 Baird Global Healthcare Conference in New York on Sept. 10, 2024. The fireside chat, moderated by Jeff Johnson, Senior Research Analyst, is scheduled for 2:00 pm Eastern Time on Tuesday, Sept. 10, and a live webcast of the presentation can be accessed here. InMode will also hold oneo ...

YOKNEAM, Israel, Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August: 9th Annual Needham Virtual MedTech & Diagnostics Conference Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual one-on-one meetings When: Monday, Aug. 12 Canaccord 44th Annual Global Growth Conference Presenters: Yair Malca, Ch ...

InMode (INMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 13.33%. A quarter ago, it was expected that this maker of cosmetic surgery devices would post earnings of $0.40 per share when it actually produced earnings of $0.45, delivering a surprise of 12.50%. Over the last four quar ...

Exhibit 99.1 InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre- orders not yet delivered) of $102.6M YOKNEAM, Israel, August 1, 2024 - InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: | U.S. GAAP Results | | | | - ...

YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Radiofrequency (RF) technology has emerged as the gold standard in skin contraction within the aesthetics industry, due to its effectiveness, safety, and minimally or non-invasive nature. RF treatments heat the deeper layers of the skin, stimulating collagen production and promoting tissue remodeling. This process results in contracted, firmer skin and a more youthful appearance. One of the primary reasons RF is favored in aesthetics is its ability to deliver consistent and noticeable results with minimal d ...

Coinciding with this clearance is the launch of the new IgniteRF and OptimasMAX platforms, which include the Morpheus8 family of handpieces. The modular portfolio of tips, including Prime 12 pin, Morpheus8 24 pin, Resurfacing 24 pin, and Morpheus8 40 pin, makes this technology a versatile solution delivering exceptional patient results. The IgniteRF and OptimasMAX platforms support 14 technologies, including minimally invasive radiofrequency assisted soft tissue coagulation and contraction, non-invasive the ...